308 related articles for article (PubMed ID: 18701918)
1. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein.
Conner J; Braidwood L; Brown SM
Gene Ther; 2008 Dec; 15(24):1579-92. PubMed ID: 18701918
[TBL] [Abstract][Full Text] [Related]
2. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
Kamiyama H; Zhou G; Roizman B
Gene Ther; 2006 Apr; 13(7):621-9. PubMed ID: 16292350
[TBL] [Abstract][Full Text] [Related]
3. Herpes simplex virus type 1 strain HSV1716 grown in baby hamster kidney cells has altered tropism for nonpermissive Chinese hamster ovary cells compared to HSV1716 grown in vero cells.
Conner J; Rixon FJ; Brown SM
J Virol; 2005 Aug; 79(15):9970-81. PubMed ID: 16014957
[TBL] [Abstract][Full Text] [Related]
4. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
5. Antibody Screening System Using a Herpes Simplex Virus (HSV)-Based Probe To Identify a Novel Target for Receptor-Retargeted Oncolytic HSVs.
Ikeda H; Uchida H; Okubo Y; Shibata T; Sasaki Y; Suzuki T; Hamada-Uematsu M; Hamasaki R; Okuda K; Yamaguchi M; Kojima M; Tanaka M; Hamada H; Tahara H
J Virol; 2021 Apr; 95(9):. PubMed ID: 33627393
[TBL] [Abstract][Full Text] [Related]
6. Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule.
Nakano K; Asano R; Tsumoto K; Kwon H; Goins WF; Kumagai I; Cohen JB; Glorioso JC
Mol Ther; 2005 Apr; 11(4):617-26. PubMed ID: 15771964
[TBL] [Abstract][Full Text] [Related]
7. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
Han ZQ; Assenberg M; Liu BL; Wang YB; Simpson G; Thomas S; Coffin RS
J Gene Med; 2007 Feb; 9(2):99-106. PubMed ID: 17256802
[TBL] [Abstract][Full Text] [Related]
8. Specific binding of baculoviruses displaying gp64 fusion proteins to mammalian cells.
Ojala K; Mottershead DG; Suokko A; Oker-Blom C
Biochem Biophys Res Commun; 2001 Jun; 284(3):777-84. PubMed ID: 11396970
[TBL] [Abstract][Full Text] [Related]
9. Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy.
Conner J; Braidwood L
Cancer Gene Ther; 2012 Jul; 19(7):499-507. PubMed ID: 22595793
[TBL] [Abstract][Full Text] [Related]
10. A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor.
Carette JE; Graat HC; Schagen FH; Mastenbroek DC; Rots MG; Haisma HJ; Groothuis GM; Schaap GR; Bras J; Kaspers GJ; Wuisman PI; Gerritsen WR; van Beusechem VW
Virology; 2007 Apr; 361(1):56-67. PubMed ID: 17184803
[TBL] [Abstract][Full Text] [Related]
11. Selection and characterization of an internalizing epidermal-growth-factor-receptor antibody.
Zhao X; Dai W; Cao L; Zhu H; Yu Y; Ye Q; Wang M; Dai W; Lei P; Shen G
Biotechnol Appl Biochem; 2007 Jan; 46(Pt 1):27-33. PubMed ID: 16886908
[TBL] [Abstract][Full Text] [Related]
12. Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy.
Afanasieva TA; Wittmer M; Vitaliti A; Ajmo M; Neri D; Klemenz R
Gene Ther; 2003 Oct; 10(21):1850-9. PubMed ID: 12960975
[TBL] [Abstract][Full Text] [Related]
13. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
[TBL] [Abstract][Full Text] [Related]
14. In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
Sorensen A; Mairs RJ; Braidwood L; Joyce C; Conner J; Pimlott S; Brown M; Boyd M
J Nucl Med; 2012 Apr; 53(4):647-54. PubMed ID: 22414636
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma.
Fu X; Nakamori M; Tao L; Amato R; Zhang X
Int J Oncol; 2007 Jun; 30(6):1561-7. PubMed ID: 17487379
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.
Mace AT; Harrow SJ; Ganly I; Brown SM
Acta Otolaryngol; 2007 Aug; 127(8):880-7. PubMed ID: 17763002
[TBL] [Abstract][Full Text] [Related]
17. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R
Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
[TBL] [Abstract][Full Text] [Related]
18. Binding activity difference of anti-CD20 scFv-Fc fusion protein derived from variable domain exchange.
Geng SS; Feng J; Li Y; Sun Y; Gu X; Huang Y; Wang Y; Kang X; Chang H; Shen B
Cell Mol Immunol; 2006 Dec; 3(6):439-43. PubMed ID: 17257497
[TBL] [Abstract][Full Text] [Related]
19. Targeting of adenoviral vectors through a bispecific single-chain antibody.
Haisma HJ; Grill J; Curiel DT; Hoogeland S; van Beusechem VW; Pinedo HM; Gerritsen WR
Cancer Gene Ther; 2000 Jun; 7(6):901-4. PubMed ID: 10880021
[TBL] [Abstract][Full Text] [Related]
20. Specifically targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene for inducible nitric oxide synthase.
Khare PD; Shao-Xi L; Kuroki M; Hirose Y; Arakawa F; Nakamura K; Tomita Y; Kuroki M
Cancer Res; 2001 Jan; 61(1):370-5. PubMed ID: 11196189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
